- Lexaria Bioscience Corp (NASDAQ:LEXX) (NASDAQ:LEXXW) announced additional findings from last year's human clinical Study HYPER-H21-4 demonstrating significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease (CVD).
- After five weeks of treatment with the patented DehydraTECH-processed cannabidiol (CBD) capsule formulation, blood-plasma levels of interleukin (IL) 8, 10, and 18 were reduced by ~19%, ~27%, and ~43%, respectively.
- Also Read: Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH.
- Those receiving five weeks of placebo experienced no significant changes in their IL levels.
- The differences evidenced relative to baseline and/or placebo with pro-inflammatory biomarkers IL 8, 10, and 18 were statistically significant.
- IL-10 levels are known to increase along with the reduction of kidney function; higher serum IL-10 levels have been associated with the risk of cardiovascular events during follow-up.
- Similarly, IL-18 is an independent predictor of cardiovascular events in patients with metabolic syndrome. In large population-based studies, circulating IL-18 is prospectively and independently associated with CVD risk.
- Lexaria previously announced that the Study's primary efficacy and safety objectives were successfully achieved, with resting blood pressure significantly reduced in hypertensive patients and sustained over the 5 weeks of dosing, with zero serious adverse events reported throughout the Study.
- Price Action: LEXX shares are up 6.60% at $0.73 on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
